Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 1/20 | 0.38 |
| ▸ | RXRB | P28702 | 1/20 | 0.38 |
| ▸ | RXRG | P48443 | 1/20 | 0.38 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.37 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.37 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.36 |
| ▸ | MPO | P05164 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SRC | P12931 | 1/20 | 0.36 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4941838 | 0.83 | AKR1B1 (0.38) | GRIK1PTGDR2ABCB11LMNAPTGS1 | |
| SCHEMBL23599468 | 0.81 | MAPT (0.43) | LMNASMN1; SMN2GAA | |
| SCHEMBL11213637 | 0.81 | FFAR1 (0.45) | RXRARXRBRXRGPTGDR2LMNA | |
| SCHEMBL15825033 | 0.79 | KDM4E (0.42) | RXRARXRBRXRGPTGDR2LMNA | |
| SCHEMBL18471266 | 0.79 | TSHR (0.46) | RXRARXRBRXRGPTGDR2AKR1B1 | |
| SCHEMBL20772954 | 0.79 | NLRP3 (0.41) | LMNASMN1; SMN2GAAMEN1KMT2A | |
| SCHEMBL3273772 | 0.78 | MPO (0.39) | LMNAMPOSMN1; SMN2GAAMEN1 | |
| SCHEMBL31434232 | 0.78 | MAOB (0.40) | PTGDR2MPOSMN1; SMN2GAA | |
| SCHEMBL17289808 | 0.78 | MPO (0.39) | LMNAMPOCHEK1 | |
| SCHEMBL4944816 | 0.76 | AKR1B1 (0.37) | GRIK1PTGDR2ABCB11LMNAPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12145924-B2 | Lysophosphatidic acid receptor 1 (LPAR1) inhibitor compounds | ELI LILLY AND COMPANY (US) | 2024-11-19 | — | — | US | disclosed |
| EP-3679032-B1 | LYSOPHOSPHATIDIC ACID RECEPTOR 1 (LPAR1) INHIBITOR COMPOUNDS | LILLY CO ELI (US) | 2023-10-04 | — | — | EP | disclosed |
| CN-111032647-B | Lysophosphatidic acid receptor 1 (LPAR 1) inhibitor compounds | 伊莱利利公司 | 2023-05-02 | — | — | CN | disclosed |
| US-20220281845-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR 1 (LPAR1) INHIBITOR COMPOUNDS | ELI LILLY AND COMPANY | 2022-09-08 | — | — | US | disclosed |
| US-11365185-B2 | Lysophosphatidic acid receptor 1 (LPAR1) inhibitor compounds | ELI LILLY AND COMPANY (US) | 2022-06-21 | — | — | US | disclosed |
| US-20200231568-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR 1 (LPAR1) INHIBITOR COMPOUNDS | ELI LILLY AND COMPANY | 2020-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220281845-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR 1 (LPAR1) INHIBITOR COMPOUNDS | LPAR1, LPAR2, LPAR5 | RXRA 1910/4885RXRB 1875/4885RXRG 1963/4885 |
| US-12145924-B2 | Lysophosphatidic acid receptor 1 (LPAR1) inhibitor compounds | LPAR1, LPAR2, LPAR5 | RXRA 1910/4885RXRB 1875/4885RXRG 1963/4885 |
| US-20200231568-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR 1 (LPAR1) INHIBITOR COMPOUNDS | LPAR1, LPAR2, LPAR3 | RXRA 1849/4885RXRB 1875/4885RXRG 1927/4885 |
| US-11365185-B2 | Lysophosphatidic acid receptor 1 (LPAR1) inhibitor compounds | LPAR1, LPAR2, LPAR3 | RXRA 1849/4885RXRB 1875/4885RXRG 1927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.